News
Helix BioPharma, a clinical-stage biopharmaceutical company, commits to innovating with purpose in this challenging landscape ...
May 1, 2025Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.51.
A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...
Community Oncology Conference, Nini Wu, MD, Navista, shares how AI can transform community oncology. The evolving role of ...
Fintel reports that on May 2, 2025, JP Morgan initiated coverage of CG Oncology (NasdaqGS:CGON) with a Overweight ...
19hon MSNOpinion
Thanks to budget cuts, many potential insights and treatments needed to propel oncology forward will never be realized.
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension ...
The Oncology Institute, Inc.’s TOI share price has surged by 10.89%, which has investors questioning if this is right time to ...
Kate Baker, MD, MMHC, medical director of value-based care at Tennessee Oncology, talks about innovations in cancer care ...
In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...
The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.
Citius Oncology, Inc.’s CTOR share price has dipped by 6.04%, which has investors questioning if this is right time to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results